2023
The relationship between reincarceration and treatment of opioid use disorder with extended-release naltrexone among persons with HIV
Parchinski K, Di Paola A, Wilson A, Springer S. The relationship between reincarceration and treatment of opioid use disorder with extended-release naltrexone among persons with HIV. Drug And Alcohol Dependence Reports 2023, 7: 100159. PMID: 37159815, PMCID: PMC10163604, DOI: 10.1016/j.dadr.2023.100159.Peer-Reviewed Original ResearchOpioid use disorderExtended-release naltrexoneXR-NTXUse disordersKaplan-Meier survival analysisHIV viral suppressionMajor depressive disorderPublic health priorityOpioid cravingViral suppressionOpioid useHIV outcomesLife scoresRetrospective studyStudy baselineDepressive disorderOdds ratioDecrease recurrenceHealth prioritySurvival analysisPWHLifetime incarcerationStudy periodMean timeDisorders
2017
Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community
Springer SA, Di Paola A, Azar MM, Barbour R, Krishnan A, Altice FL. Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community. Drug And Alcohol Dependence 2017, 174: 158-170. PMID: 28334661, PMCID: PMC5407009, DOI: 10.1016/j.drugalcdep.2017.01.026.Peer-Reviewed Original ResearchConceptsHeavy drinking daysAlcohol use disorderFirst heavy drinking dayExtended-release naltrexoneXR-NTXDrinking daysPlacebo groupAlcohol consumptionDrinks/drinking dayPlacebo-controlled trialSerious adverse eventsDrinks/daySignificant differencesMonthly injectionsAdverse eventsHIV diseaseHIV outcomesTreatment armsAlcohol scoresMAIN OUTCOMEAlcohol consumption scoresUse disordersImprovement scoresDrinking outcomesNaltrexone